Shenzhen Aile Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shenzhen Aile Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include TRU LEIYK. The owner is based in Shenzhen, Guangdong.

Room 101, Building 10, Xinyuan Villa, Minzhi Community, Minzhi Street, Longhua District

Shenzhen, Guangdong 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

TRU LEIYK
TRU LEIYK
Registered 2025

Trademark Classifications

Shenzhen Aile Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Shenzhen Aile Biotechnology Co., Ltd. have?

Shenzhen Aile Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Aile Biotechnology Co., Ltd. file in?

Shenzhen Aile Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Shenzhen Aile Biotechnology Co., Ltd.'s most well-known trademarks?

Shenzhen Aile Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as TRU LEIYK. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Aile Biotechnology Co., Ltd.'s trademark registration success rate?

Shenzhen Aile Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.